Optimind Pharma Corp. reported earnings results for the third quarter and nine months ended November 30, 2023. For the third quarter, the company reported sales was CAD 0.026673 million compared to CAD 0.059831 million a year ago. Net loss was CAD 0.104419 million compared to CAD 0.316607 million a year ago. Basic loss per share from continuing operations was CAD 0.001 compared to CAD 0.003 a year ago.
For the nine months, sales was CAD 0.095299 million compared to CAD 0.127446 million a year ago. Net loss was CAD 0.691576 million compared to CAD 1.09 million a year ago. Basic loss per share from continuing operations was CAD 0.007 compared to CAD 0.014 a year ago.